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Objectives: S100A4 has been recently identified as an adipokine associatedwith insulin
resistance (IR) in adult subjects with obesity. However, no data about its levels in children
with obesity and only a few approaches regarding its potential mechanism of action have
been reported. To obtain a deeper understanding of the role of S100A4 in obesity, (a)
S100A4 levels were measured in prepubertal children and adult subjects with and without
obesity and studied the relationship with IR and (b) the effects of S100A4 in cultured
human adipocytes and vascular smooth muscle cells (VSMCs) were determined.
Methods: Sixty‐five children (50 with obesity, age 9.0 ±1.1 years and 15 normal
weight, age 8.4 ±0.8 years) and fifty‐nine adults (43 with severe obesity, age 46- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Europeo de Desarrollo Regional (FEDER)±11 years and 16 normal weight, age 45 ±9 years) were included. Blood from children
and adults and adipose tissue samples from adults were obtained and analysed.
Human adipocytes and VSMC were incubated with S100A4 to evaluate their
response to this adipokine.
Results: Circulating S100A4 levels were increased in both children (P = .002) and
adults (P < .001) with obesity compared with their normal‐weight controls. In subjects
with obesity, S100A4 levels were associated with homeostatic model assessment‐
insulin resistance (HOMA‐IR) in adults (βstd = .42, P = .008) but not in children (βstd
= .12, P = .356). Human adipocytes were not sensitive to S100A4, while incubation
with this adipokine significantly reduced inflammatory markers in VSMC.
Conclusions: Our human data demonstrate that higher S100A4 levels are a marker
of IR in adults with obesity but not in prepubertal children. Furthermore, the in vitro
results suggest that S100A4 might exert an anti‐inflammatory effect. Further studies
will be necessary to determine whether S100A4 can be a therapeutic target for
obesity.
KEYWORDS
insulin resistance, obesity, prepubertal children, S100A41 | INTRODUCTION
According to updated World Health Organization (WHO) reports,
overweight and obesity worldwide have almost tripled since 19751.
In 2016, more than 1.9 billion adults (older than 18 years) were over-
weight, and out of these, 650 million were obese. The problem is not
only increasing in adults but also in adolescent and children (5‐18
years), where more than 340 million were either overweight or obese
in 2016.1 Hallmarks of the obesity state, including visceral fat accumu-
lation and low‐grade chronic inflammation, are associated with
increased secretion of pro‐inflammatory cytokines and the develop-
ment of metabolic diseases including cardiovascular disease and type
2 diabetes (T2D).2,3
The pro‐inflammatory state plays an important role in insulin resis-
tance,2 but the link between obesity and the development of T2D is
not well‐characterized. It is known that white adipose tissue (WAT)
has an endocrine role through the secretion of signalling molecules
such as adipokines by adipocytes and other cell types present in adi-
pose depots. These molecules participate in a hormonal network com-
municating several tissues and organs including muscle, liver, and
brain.4 Moreover, adipose tissue expansion occurring during obesity
also leads to immune cell recruitment. Therefore, adipose tissue may
be considered an immunological organ since these immune cells can
secrete pro‐inflammatory and anti‐inflammatory cytokines affecting
adipocyte biology, metabolism, and systemic inflammation, and being
a key factor in insulin resistance development and obesity‐related
pathologies.2,5 However, some patients with obesity show normal glu-
cose homeostasis,6 and previously unrecognized molecules could be
involved in this situation. Moreover, browning of subcutaneous WAT(appearance of thermogenic beige/brite adipocytes in WAT depots)
has been associated with protection against obesity and improvement
of associated metabolic alterations.7 Finally, angiogenesis is a key pro-
cess required for adipogenesis in vivo and has an important role in
inflammation‐induced adipose tissue expansion.8 In the normal weight
state, adipose tissue is a well‐vascularized tissue.9 During the early
stages of obesity development, angiogenic factors are overexpressed
to facilitate healthy adipose tissue expansion and confer protection
from metabolic insults.10 Therefore, a better understanding of adipose
tissue endocrine, immunological and angiogenic capability, and the
identification of novel potential biomarkers and therapeutic targets
to prevent and treat T2D is one of the goals in obesity field.
S100A4 is a member of the S100 calcium‐binding protein family
and has been reported to be involved in controlling cell growth, differ-
entiation, survival, and migration in different cell types, as well as in
energy metabolism.11,12 S100A4 was identified by Ebradlize and col-
leagues as a protein associated with tumour metastasis.13 S100A4
binds to cytoskeletal proteins including F‐actin14 and nonmuscle myo-
sin heavy chains.15 S100A4 gene expression is elevated in activated
macrophages.16 A recent report has identified S100A4 as a cytokine
secreted by adipose tissue mainly by precursors and immune cells,
with a potential role as a marker of subcutaneous WAT dysfunction
and insulin resistance in adult individuals with severe obesity.17 More-
over, a study performed in mice postulates that S100A4 protects
against diet‐induced obesity and inflammatory state.18
In this study, our hypothesis was that S100A4 would be elevated
and directly correlated to insulin resistance in children with obesity
as well as in adults. To address this hypothesis, S100A4 levels in chil-
dren and adult patients with and without obesity were quantified and
TAXERÅS ET AL. 101their relationship with insulin resistance was determined. Moreover,
the effects of S100A4 in human adipocytes and vascular smooth mus-
cle cells (VSMCs) were studied.2 | MATERIALS, SUBJECTS AND METHODS
2.1 | Children study
Data from this cohort have been previously published, reporting the
effects of lifestyle intervention on the metabolomic profiles in blood
and urine.19,20 In the present study, we quantified S100A4 levels in
the blood samples to evaluate potential associations with glucose
homeostasis. Briefly, children attending the Obesity Unit at the Sant
Joan de Déu Hospital were recruited between January 2013 and
December 2014. All parents signed the informed consent form. Inclu-
sion criteria were (a) age from 7 to 10 years of age; (b) with obesity,
defined as body mass index‐standard deviation score (BMI‐SDS)
greater than 2 standard deviations for a given age and sex, using the
WHO standards; and (c) prepubertal, defined as Tanner stage I breast
development for girls and testicular volume less than 4 mL in boys.
Exclusion criteria included any form of endocrine obesity, major con-
genital or chronic disease, drug‐induced obesity, use of drugs for
weight loss, or involvement in another weight‐loss programme. Fifty‐
three children with obesity were initially enrolled in the study; plasma
samples were available from 50 of these subjects at the hospital's
Biobank. Fifteen prepubertal normal‐weight children (BMI‐SDS
between −1 and 1 standard deviations) between 7 and 10 years of
age were also recruited for the study. Plasma samples from all subjects
were obtained in the morning after an overnight fast by qualified per-
sonnel at the hospital.2.2 | Adult subjects study
All participants gave their written informed consent before collecting
clinical data. Forty‐three patients (11 males and 32 females) with
severe obesity were included in this study. Ten of them were diag-
nosed with T2D, and eight had pre‐diabetes. All the patients were
evaluated by the same endocrinologist (S. P.) following the institutional
protocol for bariatric surgery between September 2012 and October
2015, according to criteria for bariatric surgery formulated in Spanish
Position Statement between Obesity, Endocrinology, Diabetes and
Surgery Societies.21 Inclusion criteria were (a) adults with BMI greater
than 35 kg m−2 and (b) adults with BMI less than 26 kg m−2 and normal
glucose levels (less than 100 mg dL−1). Exclusion criteria included any
form of endocrine obesity, major congenital or chronic disease, drug‐
induced obesity, use of drugs for weight loss, or involvement in
another weight‐loss programme. Demographic and clinical data,
including age, history of diabetes, and hypertension were prospec-
tively recorded in all subjects. Visceral adipose tissue was obtained
from a subset of these patients (n = 16). These samples were collected
during bariatric surgery and frozen at −80°C until they were used. Six-
teen normal‐weight healthy subjects were included as a control groupto measure circulating levels of our molecule of interest. Plasma sam-
ples were collected after a 12‐hour fasting and stored at −80°C in the
Biobank for the Health Sciences Research Institute Germans Trias i
Pujol Foundation.
2.3 | Circulating parameters
Glucose, insulin, and glycated haemoglobin (HbA1c) levels were mea-
sured in the certified core clinical laboratory at the hospital. The
homeostatic model assessment‐insulin resistance (HOMA‐IR) was
calculated.
S100A4 circulating levels were measured using a human protein
S100A4 ELISA kit (Cusabio Biotech Co, LTD, China). High molecular
weight (HMW) adiponectin levels were measured using a human pro-
tein HMW‐adiponectin ELISA kit (R&D Systems, China).
2.4 | Cell culture
2.4.1 | Human aortic VSMCs
Human aortic VSMCs were obtained by using a modification of the
explant technique and cultured as previously described.22 Human
VSMC were obtained from nonatherosclerotic aortas of hearts
removed on occasion of transplant surgery at the Hospital de la Santa
Creu i Sant Pau (Barcelona, Spain) and cultured in M199 (Gibco, Carls-
bad, CA, USA) supplemented with 20% fetal calf serum (FCS), 2%
human serum, 2 mmol L−1 L‐glutamine, and antibiotics as previously
described (22). Cells from four different donors between passages 3
and 6 were seeded in six‐multiwell plates. Subconfluent cells were
starved in medium supplemented with 1% fetal bovine serum (FBS)
for 24 hours prior to the addition of S100A4 (37.5, 75, or 150 ng
mL−1) recombinant protein (R&D Systems) or vehicle (phosphate‐buff-
ered saline [PBS] 1×) for 24 hours in the presence or absence of
TNF‐α (50 ng mL−1) (Sigma Aldrich) used as positive controls of inflam-
matory stimuli.
2.4.2 | Human adipocytes
Human SGBS23 were used as a model of human adipocyte cells in cul-
ture. Cells were maintained with DMEM/F12 supplemented with 10%
heat‐inactivated FBS, 32μMbiotin and 16μMpantothenic acid. For dif-
ferentiation, cells were incubated with DMEM/F12 supplemented with
32μM biotin, 16μM pantothenic acid, 25nM dexamethasone, 500μM
IBMX, 2μM rosiglitazone, 10 μg mL−1 transferrin, 20μM insulin,
100nM cortisol, and 0.2nM T3 for 7 days. Cells were then incubated
with DMEM/F12 supplemented with 32μM biotin, 16μM panthotenic
acid, 10 μg mL−1 transferrin, 20μM insulin, 100nM cortisol, and 0.2nM
T3 for seven more days or until they reach more than 90% of differen-
tiation, where indicated cells were treated with 1mM cAMP (Sigma‐
Aldrich) and S100A4 (150 ng mL−1 and 750 ng mL−1) for 6 and 24 hours
or with 1μM CL316.243 (Cayman Chemicals) for 24 hours for acute
response. Cellswere treatedwith S100A4 (150 and 750 ngmL−1) during
all the differentiation process for chronic response.








Age, y 8.4 (0.8) 9.0 (1.1) .060
Sex (F/M) 7/8 28/22 n.a.
BMI‐SDS 0.04 (0.86) 3.41 (0.75) <.001
Glucose, mg dL−1 86 (6) 85 (8) .620
Insulin, m.u.int/L 3.1 (1.6) 13.4 (6.6) <.001
HbA1c, % 5.3 (0.2) 5.3 (0.2) .891
HOMA‐IR 0.67 (0.36) 2.82 (1.44) <.001
Triglyceride,a mg
dL−1
43 [15] 70 [36] <.001
LDL‐Cho, mg dL−1 91 (19) 103 (23) .054
HDL‐Cho mg dL−1 62 (11) 44 (10) <.001
Cholesterol mg dL−1 162 (21) 164 (24) .770
S100A4,a ng mL−1 48 [28] 74 [39] .002
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Visceral adipose tissue or cells were collected in liquid nitrogen. Total
RNA was extracted using a column‐affinity–based methodology
(NucleoSpin RNA II; Macherey‐Nagel, Duren, Germany). RNA yield
was determined by spectrophotometry (NanoDrop). Five hundred
nanograms of total RNA was retrotranscribed into cDNA using ran-
dom hexamer primers and Multiscribe reverse transcriptase (TaqMan
reverse transcription reagents, Thermo Fisher Scientific), following
the manufacturer's instructions. Platinum Quantitative PCR
SuperMix‐UDG with ROX reagent (Themo Fisher) was used as master
mix reagent and expression levels of each gene of interest were
assessed with the specific TaqMan probes (Thermo Fisher). mRNA
levels of browning markers including uncoupling protein 1 (UCP1), per-
oxisome proliferator‐activated receptor gamma coactivator 1‐alpha
(PGC‐1α) and inflammatory markers including monocyte
chemoattractant protein‐1 (MCP‐1/CCL2), interleukin‐6 (IL‐6), or adi-
pogenesis markers such as adiponectin (ADIPOQ) were assessed.
HMW‐Adp,a ng mL−1 5208 [3902] 3496 [2477] .006
Adults Normal weight (n = 16) Obesity (n = 43)
Age, y 45 (9) 46 (11) 0.933
Sex (F/M) 13/3 32/11 n.a.
BMI, kg m−2 24.2 (2.3) 45.7 (7.4) <.001
Glucose, mg dL−1 89 (8) 109 (29) .002
Insulin, m.u.int/L 6.9 (4.9) 14.0 (15.6) .008
HbA1c, % 5.2 (0.2) 5.8 (0.8) <.001
HOMA‐IR 1.6 (1.3) 4.0 (5.2) .003
Triglyceride,a mg
dL−1
62 [20] 127 [53] <.001
LDL‐Cho, mg dL−1 103 (23) 98 (34) .516
HDL‐Cho, mg dL−1 67 (15) 42 (9) <.001
Cholesterol, mg dL−1 188 (30) 164 (38) .021
S100A4,a ng mL−1 52.5 [33.8] 114.8 [86.6] <.001
HMW‐Adp,a ng mL−1 5917 [4651] 3042 [1984] .008
Note. Data for normally distributed variables are shown as mean (SD), and
two‐tail Student's t test was applied to compare groups.2.5 | Statistical analysis
Unless otherwise stated, data are presented as mean ± SEM. Normal-
ity was tested using the Shapiro‐Wilk test. To analyse potential asso-
ciations with other variables, standard least‐squares linear regression
in JMP v14.1 was performed (SAS Institute Inc, Cary, NC) with log‐
transformed circulating S100A4 levels as the independent variable,
sex, age, and BMI (BMI‐SDS for children) as covariates, and either
HOMA‐IR, insulin, HbA1c, or HMW‐adiponectin (HMW‐Adp) as the
independent variable. Two‐tailed test, Mann‐Whitney U test for
non‐normal distributed data, or one‐way ANOVA with Tukey's post
hoc test for more than two groups were applied to determine statisti-
cal significance. P < .05 was considered significant for all analyses.
The Institutional Ethics Committee, in accordance with the Decla-
ration of Helsinki, approved the study with adult subjects (CP15/
00106 and PI17/01455). The children cohort study was approved by
the Sant Joan de Déu Hospital's Ethic Committee (Comité Ètic d'
Investigació Clínica—CEIC PIC‐21‐12).Abbreviations: BMI‐SDS, standardized body mass index; HbA1c, glycated
haemoglobin; HDL‐Cho, high‐density lipoprotein; HMW‐Adp, high molec-
ular weight adiponectin; HOMA‐IR, homeostatic model assessment‐insulin
resistance; LDL‐Cho, low‐density lipoprotein.
aNon‐normally distributed variables are shown as median [IQR], and
groups were compared using the two‐tail Mann‐Whitney U test. Bold font
indicates P < .05.3 | RESULTS
3.1 | Circulating S100A4 levels are elevated in both
prepubertal children and adult subjects with obesity
Both prepubertal children and adultswith obesity showed higher insulin
resistance (estimated byHOMA‐IR) comparedwith their normal‐weight
counterparts (Table 1). However, glucose and HbA1c levels in children
with obesity were not altered compared with their normal‐weight con-
trols, while they were significantly elevated in adults with obesity
(Table 1). Both children and adults with obesity showed higher triglycer-
ide levels, lower HDL‐cholesterol, and lower HMW‐Adp concentration
than normal‐weight subjects (Table 1). Circulating S100A4 concentra-
tion was measured and significantly elevated levels in both prepubertalchildren (1.5‐fold, P = .002) and adult subjects with obesity (2.2‐fold,
P < .001, Table 1) were found compared with normal‐weight controls.3.2 | S100A4 levels are associated with HOMA‐IR in
adults but not in prepubertal children
Then the association between circulating S100A4 levels and insulin
resistance in the two different cohorts was tested. Given that obesity
FIGURE 1 S100A4 is expressed in visceral
white adipose tissue (vWAT) and correlates
with circulating levels and homeostatic model
assessment‐insulin resistance (HOMA‐IR). (A‐
B) Bivariate correlation plots between log‐
transformed circulating S100A4 levels and
HOMA‐IR in (A) adults and (B) children with
obesity. (C‐D) Bivariate plot between S100A4
mRNA in vWAT and (C) circulating levels and
(D) HOMA‐IR. S100A4 gene expression is
expressed as arbitrary units of S100A4 mRNA
levels relative to the expression of the
housekeeping transcript PPIA. *P < .05
TAXERÅS ET AL. 103has a major impact on both S100A4 levels and insulin resistance, the
focus of the analysis was on subjects with obesity to avoid this con-
founding factor. Circulating S100A4 levels were strongly correlated
to HOMA‐IR in adult subjects with obesity (Figure 1A) and were
maintained after adjusting for sex, age, and BMI (βstd = .42, P =
.008, Table 2). However, no correlation between S100A4 and
HOMA‐IR was found in prepubertal children with obesity (Figure 1B)
before or after adjusting for sex, age, and BMI‐SDS (βstd = .12, P =
.356, Table 2). A modest trend towards a correlation with HMW‐
Adp was observed in children, without reaching statistical significance
(βstd = .27, P = .061, Table 2).3.3 | S100A4 gene expression in WAT is associated
with S100A4 circulating levels and HOMA‐IR in adult
subjects with obesity
To evaluate the potential role of WAT in S100A4 secretion, S100A4
mRNA levels were measured in visceral WAT (vWAT) samples from
adult patients with obesity. S100A4 expression in this tissue showed
a positive correlation with its circulating levels and HOMA‐IR
(Figure 1C,D).TABLE 2 Correlations between circulating S100A4 levels and phys-
iologic variables
S100A4 Children Adults
Variables βstd P value βstd P value
HOMA‐IR .12 .356 .42 .008
Insulin .06 .650 .43 .008
HbA1c .13 .391 .25 .106
HMW‐Adp .27 .061 .16 .4453.4 | S100A4 exerts anti‐inflammatory effects in
vascular smooth‐muscle cells in vitro
Since WAT seems to play a role in the secretion and function of
S100A4, the aim was to evaluate the effects of this adipokine in two
different cell types with a relevant role in adipose tissue expandability
during obesity: adipocytes and VSMC. For these experiments, human
adipocytes and VSMC were incubated with S100A4 for 24 hours
(acute) or during 1 week of differentiation for human adipocytes
(chronic). No effects were found in UCP1, PGC‐1α, CCL2, IL‐6, or
ADIPOQ in human adipocytes (Figure 2). In human VSMC, a dose‐
response curve with 37.5, 75, and 150 ng mL−1 of S100A4 for 24
hours was performed, showing that only the incubation with 75
and 150 ng mL−1 significantly decreased CCl2, IL‐6, and IL‐1β mRNA
levels. No effect was observed with the lowest dose of S100A4
(37.5 ng mL−1). Furthermore, only the dose of 150 ng mL−1 partially
blocked the increase of CCl2 and IL‐6 (but not IL‐1β) expression
induced by incubation with TNF‐α, used as a positive control for
inflammation (Figure 3).4 | DISCUSSION
To the best of our knowledge, this is the first time that S100A4 circu-
lating levels are reported to be elevated in prepubertal children with
obesity compared with normal weight healthy controls. As expected
from previously published data (ref Arner), S100A4 levels were also
elevated in our cohort of adult patients with severe obesity compared
with normal‐weight controls and showed a correlation with insulin
resistance. Surprisingly, the association between S100A4 and insulin
resistance was not present in children.
S100A4 levels have been reported to be increased in human adults
with obesity, being positively associated with sWAT dysfunction,
FIGURE 2 Treatment with S100A4 does not cause changes in human adipocytes. (A) Relative mRNA levels of different markers of adipogenesis,
thermogenic capacity, and inflammation in human adipocytes treated with 150 or 750 ng mL−1 S100A4 for 24 hours or during differentiation,
where indicated. Expression was normalized to 18S. (B) Representative optical microscopy images from beige adipocytes treated with 750 ng mL−1
S100A4 since day 1 of differentiation. (*P < .05) relative to control. The bars represent means ± SEM
TAXERÅS ET AL.104inflammation, and insulin resistance.17 Other researchers have shown
that S100A4 deficient mice were more susceptible to develop obesity
and insulin resistance after a high‐fat diet, suggesting a protective role
for S100A4 in diet‐induced obesity.18 Furthermore, overexpressed
S100A4 inhibited adipogenesis and decreased inflammatory markers
in 3T3‐L1 adipocytes.18 Our results suggest a potential explanation
for the controversial role of S100A4 in obesity and insulin resistance.
Our cohort of children with obesity showed hyperinsulinaemia, but
this excess of insulin secretion was able to maintain normal glucose
levels. Researchers have reported an induction of adiponectin by
S100A4 in 3T3‐L1 adipocytes and in mice.18 Although there was noFIGURE 3 Treatment with S100A4 reduces the expression of pro‐inflam
Human VSMCs were exposed to S100A4 (37.5, 75, or 150 ng mL−1) or/an
by real‐time PCR and normalized to GAPDH 24 h after incubation with S10
assessed by real‐time PCR and normalized to GAPDH 24 h after incubation
as mean ± SEM (n = 5); one‐way ANOVA was implemented to compare diff
vs TNF‐α)correlation between S100A4 and HMW‐Adp, it is plausible that the
elevated S100A4 levels may play a beneficial role during early states
of obesity in an attempt to balance the hyperinsulinaemia and the
potential development of insulin resistance in this population in which
obesity is only at the beginning of eliciting metabolic dysfunction.
Moreover, our in vitro experiments demonstrate a beneficial direct
effect of S100A4 on VSMC by reducing inflammatory markers.
S100A4 is secreted by adipocyte precursors and immune cells17 and,
during obesity, both an alteration of adipogenesis and the recruitment
of immune cells occur (reviewed in24). In addition, new blood vessel
formation (angiogenesis), including VSMC, is required for a correctmatory marker genes in human vascular smooth muscle cell (VSMC).
d TNF‐α for 24 h. (A‐C) Expression of CCL2, IL6, and IL1β assessed
0A4 (37.5, 75, or 150 ng mL−1). (D‐F) Expression of CCL2, IL6, and IL1β
withTNF‐α or TNF‐α + S100A4 (75 or 150 ng mL−1). Values are shown
erent treatments (***P < .001, **P < .01, and *P < .05 vs vehicle; #P < .05
TAXERÅS ET AL. 105adipose tissue expandability.25 Moreover, inflammation and vascular
dysfunction contribute to the development of obesity and insulin
resistance.26 Therefore, it is tempting to speculate that S100A4 secre-
tion by immune cells infiltrated in adipose tissue during obesity acts on
VSMC and thereby regulates the vascular tone, distribution of blood
flow, as well as angiogenesis, inflammatory processes, and redox sta-
tus. It is plausible that that this beneficial effect could contribute to
improving the inflammatory state during the early stages of obesity
development, delaying the development of adipose tissue dysfunction
and insulin resistance.
In accordance with other researchers,17 no direct effect of S100A4
on adipocytes was observed possibly due to the lack of specific recep-
tors, suggesting that these cells are not a target for S100A4 action. In
agreement with Arner et al,17 who postulated that S100A4 is an
adipokine, our data showed that S100A4 is expressed in WAT. In addi-
tion, S100A4 vWAT gene expression correlated with circulating levels,
suggesting that vWAT is a source of circulating S100A4. Moreover,
S100A4 mRNA and circulating levels positively correlated with glu-
cose homeostasis parameters, suggesting a role of this adipokine in
the metabolic status of these patients. An intriguing possibility is that
a chronic release of this molecule in the obesity status could lead to an
S100A4 resistant situation, in a similar way to what has been shown
for other molecules including leptin and FGF21.27,28 Further studies
are warranted to determine the occurrence of an S100A4 resistant
state in obesity.
The limitations of this study include the lack of adipose tissue sam-
ples in children to analyse the molecular mechanisms involved in the
elevation of S100A4 and the lack of correlation with insulin resistance.
Moreover, HOMA‐IR was used as a marker of insulin resistance due to
the lack of a clamp assay. Another important limitation is that our vas-
cular cellular model comes from aorta and not from adipose tissue ves-
sels. In addition, longer and chronic S100A4 exposure would be
desirable to evaluate the long‐term effect of S100A4 in vitro. The
strengths include the large cohort of plasma samples from prepubertal
children with obesity and the availability of additional physiologic
parameters allowing to identify the associations between S100A4
and other surrogates of metabolic state.
In conclusion, our human data demonstrate for the first time that
S100A4 circulating levels are higher in children with obesity compared
with normal‐weight individuals but do not correlate with insulin resis-
tance as in adult subjects. Moreover, our in vitro results suggest a
potential anti‐inflammatory effect of S100A4 in VSMC. Further stud-
ies will be necessary to determine whether S100A4 can be a thera-
peutic target for obesity and the development of insulin resistance
associated with this condition.AUTHOR CONTRIBUTIONS
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